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Cardiovascular disease is among the leading causes of death in the US. It stems from the
pathological buildup of plaque within the vasculature known as vascular calcification. Medial
calcification, or arteriosclerosis is the buildup of plaque within the medial layer of the arteries
resulting in artery wall stiffening and reduction of blood flow. Evidence suggests that the
vascular smooth muscles cells (VSMCs) that line the medial layer of the arteries, undergo a
phenotypic switch to osteoblast-like cells to deposit calcium while in this pathological state. The
Wnt/-catenin pathway could potentially play a role in the phenotypic modulation. Inhibition of
the Wnt signaling pathway could be a promising approach to combat vascular calcification.
Sclerostin (SOST) has been shown to be upregulated during arteriosclerosis in a manner that is
indicative of the possible therapeutic potential of the protein. Therefore, we propose to confirm
the role of Wnt signaling in vascular calcification and investigate the effects of SOST treatment
on vascular calcification.
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CHAPTER I
INTRODUCTION
Background
Cardiovascular disease (CVD) remains among the top 2 leading causes of death in the
United States since 1975, with 1 out of 4 deaths being contributed to heart disease [1], [2].
Although, according to the World Health Organization (WHO), CVD still claims the title as
being the number 1 cause of death globally, estimating a total of over 17 million deaths in 2015
[1]. Such diseases include myocardial infarction, angina, and stroke [2]. These often-fatal events
can result from the underlying pathological condition known as vascular calcification, or the
deposition of calcium in the walls of the vasculature that causes a pathological state [2], [3].
Vascular Calcification
Vascular calcification was originally considered a passive, degenerative process,
however, is now deemed an active biological process [2] – [4]. Nonetheless, due to the broad
nature of vascular calcification, it is important to differentiate between the types of the
pathological condition. Intimal and medial are two prominent types of calcification. Intimal
calcification, or atherosclerosis, features endothelial dysfunction, inflammation, and intimal
thickening usually resulting from endothelial damage due to high blood pressure, smoking,
or excess cholesterol, fats, and glucose within the blood [2], [3], [5]. It is characterized by the
accumulation of plaque; cholesterol, calcium, fats, and other substance within the blood;
along the walls of the endothelium within the arteries [3], [4], [6]. Alternatively, medial
1

calcification, or arteriosclerosis is characterized by the stiffening of the walls within the
medial layer of the arteries due to calcification in the area [3]. As a result of arteriosclerosis,
there is a reduction of blood flow which leads to increased cardiovascular mortality with
illnesses including chronic kidney disease, diabetes, hypertension, and even coronary heart
failure [3], [4]. Withal, intimal and medial calcification should not be considered mutually
exclusive events. In theory, stress generated from intimal calcification causes vascular
smooth muscle cells (VSMCs) lining the medial layer of the arteries to undergo a phenotypic
switch causing them to lose their contractile properties and, in response, induce medial
calcification [7]. For this study, however, the primary focus will be calcification of the
medial layer.
Medial vascular calcification theoretically mimics the ossification processes of bone
remodeling attributing to the active buildup of hydroxyapatite [2], [8]. Osteogenesis, or the
formation of bone utilizes mesenchymal stem cells which differentiate into osteoblasts, or
bone-forming cells to promote ossification [2], [8]–[10]. This process involves transcription
factor, Runx2, which is necessary to promote differentiation to osteoblasts [9], [10]. In the
same manner, VSMCs, which are responsible for the physiological functioning of the medial
layer of the arteries, undergo a phenotypic switch to osteoblast-like cells to deposit calcium
whilst in a pathological state [11]. That is, VSMCs can reversibly switch from a contractile
to a synthetic phenotype under stress conditions [12]–[14]. This phenotypic modulation
includes deviating from possessing adaptability to the flow of blood, to becoming
proliferative, resulting in thickening and stiffness of the arterial wall [14]. Figure 1 contrasts
the morphology of contractile and synthetic VSMCs. Moreover, studies have shown an
upregulation of osteoblast-like markers and loss of contractile markers within these synthetic
2

VSMCs, further implicating that the process of ossification serves as a promising model to
study the mechanism by which medial calcification occurs [8], [14]. Though, within
osteogenesis, there is also regulation that acts in the event of excess and insufficient bone
buildup to maintain bone homeostasis. These regulation factors such as osteoblasts or
osteoclasts, bone-forming and bone dissolving cells, are not present within the vasculature
when there is an accumulation of hydroxyapatite due to calcium deposition [15].
Consequently, the build-up causes turbulent or inappropriate blood flow leading to the
different cardiovascular conditions and events.

Figure 1

Contractile vs. Synthetic Vascular Smooth Cells.

The figure highlights the differences between contractile and synthetic phenotypes amongst
vascular smooth muscle cells. Adapted from [16].

3

The exact mechanisms by which vascular calcification occurs are unknown, however,
because of its similarities to bone formation, it is appropriate to hypothesize that they occur
by the same system. As previously mentioned, Runx2 is a transcription factor necessary for
osteoblast differentiation. Studies have shown that Runx2 is in direct association with the
Wnt/βcatenin signaling pathway, eluding that the pathway mediates bone formation by
activating Runx2 to regulate the differentiation of mesenchymal stem cells to an osteogenic
lineage [9], [10]. Thus, evidence suggest that calcification within the arteries potentially
forms through the Wnt-signaling pathway.
Wingless (Wg)/Wnt-Signaling Pathway
Wnt signals activate transcriptional pathways that may promote developmental
processes such as cell proliferation of tissue expansion [2]. There is no limit on the type of
process that may be executed by Wnt signaling because the pathway can potentially impact
the cell at various points during the life cycle [2], [17], [18]. It has been previously shown
that Wnt signals have the ability to shape tissues that are growing while also instructing cells
to proliferate and even maintain the tissue architecture in adult life, implying that even fate
determination can be influenced by the Wnt signaling pathway [2].
The Wingless family of proteins consists of 19 lipid-modified glycoproteins [2], [17].
The Wnt cascade activates when one of these secreted glycoproteins binds to Frizzled (Fzd)
and the coordinating coreceptor complex, depending on which Wnt pathway is being
activated. Fzd functions as a signal-transducing protein that is found at the surface of the
plasma membrane of Wnt-responsive cells [19]. Once Wnt proteins bind to Fzd and their
corresponding co-receptor complex, a signal is transduced into the cell to target the
4

cytoplasmic protein, Disheveled (Dsh or Dvl), which acts as an interpreter of the signals to
guide the activation of the correct pathway [20]. From this point, the signal branches of into
one of the three major Wnt signaling pathways: the noncanonical planar cell polarity
pathway, the Wnt/Ca2+- pathway, and the canonical Wnt/βcatenin pathway [18]. Figure 2
displays the three different pathways, as well as the mechanism by which they are activated.

Figure 2

Wnt-Signaling Pathways

Wnt/β-catenin pathway. (B) Planar Cell Polarity Pathway. (C) Wnt/Ca2+ pathway. Source:
Adapted from [21].
Non-Canonical (Wnt/Ca2+-) and Planar Cell Polarity Pathway
The non-canonical pathway consists of two distinct Wnt cascades that are independent of
β-catenin. In the Wnt/Ca2+- pathway, Wnt binds to the extracellular cysteine rich domain on the
N-terminus of its cognate Fzd receptor, promoting interaction with Dsh and mediating the
phosphorylation of the receptor tyrosine [2]. After phosphorylating tyrosine, the signal then
5

interacts with calcium channels to release Ca2+ [2]. Research has found that the Wnt/Ca2+
pathway functions during embryogenesis in promoting cellular fate, regulate tissue separation,
and formation of the heart [22]. The planar cell polarity pathway is assumed to be mediated
through Fzd, but independent of a coreceptor complex [18]. Its implication through the Wnt
signaling pathway starts with the activation of small GTPases, Rho and Rac, which mediate
cytoskeletal rearrangements [2].
Canonical Pathway (Wnt/β-catenin)
The canonical (Wnt/β-catenin) pathway is the most studied pathway and is implicated
in many developmental processes, including bone metabolism [2], [17], [18]. β-catenin, a
cytoplasmic protein, is the central player in the canonical Wnt cascade [10], [18]. Within this
pathway, Wnt binds to Fzd and the LRP 5/6 coreceptor complex to activate Dsh, which in
response causing the inactivation GSK3, a “cytoplasmic destruction complex” [2], [17]. The
complex is responsible for regulating the phosphorylation of the β-catenin protein and
targeting it for degradation [23]. Therefore, since the complex is inactive when Wnt is
bound, stable β-catenin accumulates in the cytoplasm to eventually translocate into the
nucleus resulting in an upregulation of Wnt target gene expression. Figure 3 below further
highlights the variances between active and inactive canonical Wnt signaling.

6

Figure 3

Active vs Non-Active Canonical Wnt-Signaling.

The figure highlights the differences among active/non-active Wnt-signaling. Source: Adapted
from [24].
As previously stated, studies have shown that Runx2 is a target gene of the Wnt/βcatenin pathway, directly influencing osteogenesis [9], [10]. This occurs through the
mechanism described above and has been found most prevalent during embryonic
development and skeletal maintenance.
Which Wnt?
There is a multitude of evidence that suggests the involvement of Wnt in vascular
calcification and identifies the specific key players relative to the pathway. It is also likely
that there are numerous signaling pathways involved in vascular calcification. However, it is
necessary to consider each of these pathways independently to further evaluate their role.
More specifically for Wnt-signaling, it is very possible that many of the Wnt glycoproteins
may play a role in calcification, however, many researchers have begun to evaluate specific
7

Wnt ligands to determine if one may contribute more towards calcification. A study
performed by Shen et al. confirmed that Wnt16 stimulates bone formation through canonical
signaling but also inhibits osteoclast activity in noncanonical signaling [25]. It was also
found that Wnt16 is expressed by VSMCs, regulated by arteriosclerotic stimuli and
contributes to aortic stiffening [26]. Wnt7b was confirmed to activate canonical signaling
within VSMCs that was shown through 8-fold activation of a TOPFLASH reporter assay
[27]. However, Wnt3a is the most studied ligand for having the most significance in vascular
calcification. Wnt3a has been shown to be significantly increased when vascular calcification
has been induced [28]. In the same study, it was also shown that the presence of Wnt3a led to
an increase in RUNX2 expression [28]. These studies suggest that the Wnt3a ligand may be
the primary focus for future studies involving vascular calcification and potential treatments.
The role of the Wnt pathway in bone formation, in general, leads to the ideal that it
could also play a role in vascular calcification due to the phenotypic switch of VSMCs to
osteoblast-like cells. If this is the case, an antagonist to the Wnt/B-catenin pathway could be
used as a therapy to reverse or limit vascular calcification.
Sclerostin (SOST)
Sclerostin (SOST) is a protein primarily expressed and secreted by mature osteocytes
functioning as an inhibitor of bone formation [29], [30]. SOST acts as an antagonist to the
Wnt/β-catenin pathway by binding to the LRP 5/6 coreceptor complex, which hinders the
attachment of Wnt to the Fzd receptor and prevents downstream signaling [29]–[31]. In
Figure 4, Sclerostin is shown connecting to LRP 4 and 5/6, ceasing the progression of the
pathway.
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Figure 4

Sclerostin Inhibition vs Active Wnt/β-catenin Signaling.

This figure highlights Wnt inactivity when SOST is present as an inhibitor. Source: Adapted
From [32].
Studies have shown that the absence of SOST expression can lead to high bone mass
that features exaggerated bone formation and excess-bone diseases [29]. Conversely, overexpression of SOST has the potential to decrease bone mass which alludes to deficient bone
formation and stability [29]. Having said that, although SOST expression is mainly seen
through mechanisms and actions of the bone, there is evidence suggesting that it can be
detected and correlated to plaque build-up associated with vascular calcification. However, if
this is the case, it is unclear whether SOST is a positive/negative inhibitor or simply a
biomarker of calcification.

9

Positive, Negative, or Biomarker
In a study conducted by Qureshi et al, they investigated the association of serum
SOST levels in patients with epigastric and coronary artery calcification to evaluate the
foretelling potential of the protein [33]. The patients consisted of adult end-stage renal
disease (ESRD) patients undergoing living donor renal transplantation. Most of the patients
were white and around the age of 46, amounting up to 89 participants total. The study
showed evidence of medial layer vascular calcification that was present in 42% of the
patients, while also suggesting a positive association between medial vascular calcification
and serum SOST levels. It was concluded that serum SOST is associated with a degree of
vascular calcification combining various different factors for ESRD patients, however its
potential as a biomarker is seemingly limited [33].
A similar study by Gaudio et al. aimed to analyze the relationship between serum
SOST levels and Dickkopf 1 (Dkk1), an additional inhibitor of the Wnt/β-catenin pathway,
using a Carotid Intima-Media Thickness (CIMT) test and their relationship with arterial
stiffness using pulse wave velocity measurements [34]. The intent was to evaluate the
possible role that SOST and Dkk1 play as a predictor of arterial stiffness. The 67 participants
resided in the urban area of Catania, Italy, and each exhibited either osteoporosis or
atherosclerosis. Those with malignant tumors, drug use, chronic kidney disease, and chronic
hepatic impairment were excluded. All patients received a carotid artery ultrasonogram in a
lying down position to measure CIMT and they were defined according to the ARIC
(Atherosclerosis Risk in Communities) clinical study [34]. The pulse wave measurement was
used to determine the central aortic pressure. Blood samples were taken after a fasting period
and used for measurement of serum albumin, phosphorus, and creatinine. The study yields
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that SOST is an independent predictor of arterial stiffness in healthy outpatient subjects. It
was also concluded that the pulse wave velocity technique is an effective test of arterial
stiffness. Although pulse wave velocity was associated with SOST serum levels, it was not
the case for Dkk1, indicating that the degree of the inflammatory response may be in regard
to the different clinical characteristics of the patients [34]. The researchers concluded that
evidence suggests that serum SOST does seem to correlate with arterial stiffness [34].
The previous studies demonstrate associations of serum SOST with vascular
calcification and arterial stiffness. Although, it was not necessarily inferred from these
studies whether the association was a result of serum SOST functioning as a defense for
vascular calcification, evidence does suggest that the upregulation of the protein is, in part,
due to existing as an intervention. Bruzzese et al. sought to study the role of SOST in uremic
patients by analyzing its behavior during a hemodialysis session while also evaluating the
correlation of its serum levels with regards to markers of uremic osteodystrophy and vascular
calcification [35]. The study consisted of 21 adult patients who received intermittent
hemodialysis treatment, excluding those diagnosed with cancer or inflammatory disease. The
sessions last 3-4 hours, 3 times a week. 20 healthy individuals were also studied as a control
group meaning that they had no history of hypertension, diabetes, etc. Blood samples were
collected before and after hemodialysis and after a fast for the control group. Interestingly,
the study yielded that SOST could be dialyzable or reduced after hemodialysis [35]. It was
also found that SOST was not exclusively produced from osteocyte cells but also from the
upregulation in VSMCs. This further suggests confirmation of the phenotypic switch of
VSMCs in regard to being regulated through the Wnt/β-catenin pathway and the role that
SOST could play in serving as a therapy for vascular calcification. Furthermore, high SOST
11

levels were also linked to inflammation, vascular lesions, and expression of other biomarkers
[35]. The study settled on the fact that hemodialysis could reduce SOST levels and that
elevated levels of the protein are independently related to vascular calcification.
A different type of study conducted by Bovijn et al. aimed to investigate the effect of
factors that increase bone mineral density within the SOST locus on the risk of bone fracture,
osteoporosis, cardiovascular events, and whether SOST inhibition therapy has a negative
effect on cardiovascular diseases [36]. They found that using a drug to lower SOST levels
lifelong does indeed prevent osteoporosis and other bone defects, however it conversely
increases the risk of cardiovascular events due to the downregulation of SOST [36]. The
researchers also suggested an extensive study into the drug “Romosozumab”, which is a
sclerostin inhibitor, to assess its effects on cardiovascular events. Though, still within this
study, it suggests that SOST has a positive independent association with vascular
calcification which is especially seen through the fact that calcification is more prevalent
when SOST is virtually absent.
In any case, it is necessary to evaluate the SOST protein in a different manner.
Glucocorticoids (GCs) are synthesized and secreted by the adrenal glands and have an
impact on the physiological functioning of several systems within the body including
metabolism, adapting to stress environments, and host defense [37]. Signaling components of
GCs can be influenced by factors including neuroinflammation, stress, and negative
feedback. It has also been shown that GCs play a vital role for bones later on in life. In the
study by Beier et al. they investigated the impact of GCs on the Wnt pathway, which is also
critical for bone formation. They examined SOST as a facilitator of the inhibitory effects of
GCs as well as whether or not the removal of SOST counteracts the inhibitory effects of
12

bone mineralization [37]. They found that GCs indeed mediate themselves by utilizing SOST
to antagonize the Wnt pathway, thus inhibiting osteoblast differentiation. An important
association of the study was highlighted when it was confirmed that SOST blocks the Wnt
pathway from advancing, which could again yield association of vascular calcification.
On the contrary, these associations of SOST with vascular calcification could just be
indicative that SOST can be utilized as a biomarker for cardiovascular events as earlier
studies sought out. Kalousova et al. aimed to investigate the prognostic significance of SOST
in hemodialysis patients. The study was performed in two dialysis centers in the Czech
Republic and consisted of 106 hemodialysis patients averaging around the age of 61. The
control group consisted of 25 healthy volunteers averaging around the age of 48. Blood
samples, vitamin D, and serum SOST was collected from all patients. It was found that
SOST concentrations were almost 3 times higher in the hemodialysis patients compared to
the controls. Higher cardiovascular risk was correlated with SOST concentrations above the
median. Overall, it was inferred that SOST is elevated in hemodialysis patients and linked to
higher cardiovascular mortality [38]. Limitations of the study include the fact the study was
observational and did not consider various confounding variables when interpreting the
results. Moreover, the researchers suggested that the elevated levels of SOST were not
necessarily protective agents against calcification but more of an indicator. However, it is
feasible to assume that SOST is only needed when levels if vascular calcification is
increased, hence, the protein levels are elevated.
In a similar study by Moghazy et al., they investigated the serum levels in both
dialyzed and non-dialyzed chronic kidney disease patients as a potential predictor of both
vascular and valvular types of calcification [39]. The participants consisted of 20 healthy
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volunteers used as a control group and 62 patients with chronic kidney disease explicitly
defined. All participants received a clinical examination, radiological investigations, and
echocardiographic assessments [39]. Laboratory investigations consist of obtaining blood
samples after periods of fasting and before and after hemodialysis sessions. A significantly
higher SOST serum level was observed in the dialyzed patients compared to those who were
not [39]. It was found that positive levels of
SOST were also associated with age and valvular calcification. The study concluded that
SOST could be used as a sensitive biomarker or both vascular and valvular calcification in
individuals with chronic kidney disease and that addressing the therapeutic potential of
SOST could be used in developing treatments for individuals with vascular calcification.
Conclusion
There is an abundance of evidence that suggests that SOST has some form of association
to vascular calcification. However, it remains unclear whether this association is positive,
negative, or simply an indication of a vascular pathological condition. Based on studies
discussed within this review, they all yield that SOST is either a positive inhibitor or could
potentially be used as a therapeutic agent for vascular calcification. Although, it is not illogical to
conclude that naturally occurring SOST should be used as a biomarker of vascular calcification.
However, perhaps this can be due to the fact that SOST is elevated in individuals because
calcification is present, and the protein is trying to act as a defense against it. Yet, there is not
enough natural SOST production to combat the calcification. If this is the case, some studies do
suggest that the possible therapeutic potential of SOST may cause a threat to established bone
within the body. This implies that while excess SOST may reverse and eliminate the effects of
vascular calcification, there may also be adverse outcomes within the bones that could lead to
14

bone diseases. It is important to note that there is still much that has not yet been discovered
regarding SOST, the Wnt-signaling pathways, and overall vascular calcification, which deems
necessary further investigation into these proteins and mechanisms. To address a few of these
points, the following specific aims have been developed:
Specific Aim 1: Characterize in-vitro model of vascular smooth cell calcification & confirm
Wnt-signaling.
Specific Aim 2: Investigate the dose dependency of Sclerostin as it affects vascular smooth
muscle cell calcification.

It is hypothesized that the previously published in-vitro model of vascular calcification
from our lab will also prove to be successful within a different lineage of VSMC. Based on
previous literature, it is also our belief that the presence of Wnt-signaling will be revealed
through the increased presence of “Wnt markers” and the reduction of VSMC markers.
Following SOST treatment, it is our belief that there will be a strong correlation between the
increasing dosages of SOST with decreasing amounts of SOST. We also hypothesize that there
will be recovery of VSMC markers and reduction of “Wnt-markers”.

15

CHAPTER II
AIM I: CHARACTERIZE IN-VITRO MODEL OF VSMC CALCIFICATION & CONFIRM
WNT-SIGNALING
Introduction
Previously reported literature from our lab has shown successful induction of healthy
VSMCs when supplemented with inorganic phosphate [40]. However, the VSMCs that were
experimented with at that time are of a different cell lineage than the cells being studied in
the lab now, although they are VSMCs. For this reason, it is necessary to reaffirm that the
previous in-vitro model will be adequate for our current cell line. This would involve
determining the best source of inorganic phosphate and the appropriate cell-culture
environment.
Inorganic phosphate (Pi) is one of the many options that have been shown to induce
calcification in VSMCs. In a study performed by Giachelli et al., they showed that cells that
were supplemented with extracellular inorganic phosphate; in levels comparable to that of
patients with hyperphosphatemia; tended to have increased levels of calcium deposition with
the cell culture [41]. It was also shown from this study that following the addition of
inorganic phosphate, cells began to behave with differing mechanical properties, such as
expression of osteogenic RUNX2 [41]. A similar study performed by Jono et al., also sought
to examine the effects of the addition of inorganic phosphate on culture mineralization [42].
They found that there was a significant increase in mineralization to cell cultures with high
16

concentrations of inorganic phosphate compared to those that were just supplemented with
normal physiological levels of inorganic phosphate [42]. Also like the previous study, there
were elevated levels of osteogenic marker expressed by cells with a higher calcium content.
Based on these studies, elevated levels of inorganic phosphate can be used as an effective
agent to induce calcification.
It is also necessary to relate the calcium content within cells to the markers they may
express. Alpha-smooth muscle actin (SMA) is a cytoskeletal actin isoform that is
predominately found is VSMCs and plays a role in myofibroblasts differentiation, focal
adhesion maturation, and the generation and transmission of mechanical forces [43]–[45]. It
is the single most abundant protein within adult VSMCs [43]. It has also been shown to be
significantly decreased prior to cells being supplemented with inorganic phosphate [43].
Axin, β-catenin, and RUNX2 on the other hand, are markers indicative of Wnt signaling.
Axin is a protein that serves 2 purposes for Wnt signaling; to promote degradation of βcatenin and to interact with LRP5/6 for the recruitment of the GSK3 “destruction complex”
to facilitate phosphorylation of LRP5/6 so that Wnt-signaling may occur [46], [47]. Studies
have shown that when GSK-3, an inhibitor of Wnt is suppressed, levels of Axin2 were
significantly increased [47]. Generally, Axin will be present during active and inactive Wnt
signaling. In a similar manner, Β-catenin is always also present in some capacity, however it
is up regulated during active Wnt-signaling due to the “destruction complex” being inactive
[45]. Studies have also shown that β-catenin and RUNX2, as previously mentioned, are both
expressed in vascular calcification [45]. Therefore, it is very reasonable to consider
visualizing or quantifying these cell markers as a means of evaluating the role of the Wntsignaling pathway in vascular calcification.
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Aim I Specific Objectives
The objectives of these studies were to first determine the appropriate source of
inorganic phosphate to promote calcification with the new line of VSMCs, as well as the
appropriate culture environment to grow VSMCs. After confirming the appropriate sources,
we then want to visualize calcium content and characterize mechanical properties of normal
versus calcified cells. Lastly, confirmation of Wnt involvement shall be confirmed through
visualizing and quantifying the common VSMC and osteogenic markers at different time
points.
Experimental Section
Materials/Methods
Cell Culture.
Human Aortic VSMCs (C-007-5C) were purchased and expanded between passage 4-7.
Cells were cultured in a standard growth medium containing Dulbecco’s Modified Eagles
Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1% Penicillin. Light microscopy was
used to visualize cell morphology. Cells were then seeded in 6-well plates with 3mL of growth
medium. Once grown to 80% confluency, plates were then rinsed with sterile Phosphate-buffered
saline (PBS) and supplemented with a “serum-starve” media for 12 hours. The “serum starve”
media contained the same components of the standard growth medium; however, it lacked the
10% FBS. After the 12 hour “starvation period”, calcification was then induced from either of
the following sources: Sodium Phosphate Dibasic Anhydrous (N37595, Mallinckrodt AR),
Sodium phosphate dibasic (S5136-500G, Sigma-Aldrich), and Sodium β-glycerophosphate
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(βGP). Cells were calcified for different time points between 0-14 days. They were fed with their
experimental media every 2-3 days.
Determination of Pi Source.
Human Aortic VSMCs were cultured and expanded to passage 4. Cells were seeded within
6-well plates and supplemented with 3mLs of the standard growth media. After reaching
80% confluency, cells were “serum starved” for 12 hours. Following the starvation period,
cells were fed with their conditional media, Sodium Phosphate Dibasic Anhydrous at 3mM,
6mM, &12mM concentrations (n=6 for each); Sodium phosphate dibasic at 3mM, 6mM, &
12mM concentrations (n=6 for each); βGP at a low 5mM & a high 10mM concentration
(n=6 for each), and Control with standard growth media (n=6). Cells were cultured for 7
days in their experimental media and fed every 2-3 days.
Determination of Culture Environment.
Studies have suggested that certain extracellular matrix molecules, such as collagen, can
promote vascular calcification and that some cells preferentially produce these matrix
components [48]. Standard glass 6-well plates were coated with Rat-Tail Collagen Coating
Solution (122-20, Cell Applications) and incubated at room temperature for 12 hours. After the
incubation period, cells were gently rinsed with PBS. Human Aortic VSMCs were cultured and
expanded to passage 6. Cells were seeded in the collagen coated 6-well plates and standard glass
6-well plates. They were supplemented with 3mLs of the standard growth media and “serum
starved” for 12 hours after reaching 80% confluency. Cells were then fed their conditional media
which consisted of either 3mM Sodium Phosphate Dibasic Anhydrous (n=6 for each) or the
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standard growth media (n=6 for each). Cells were cultured for 7 and 14 days in their
experimental media and fed every 2-3 days.
Quantification of Mineral Deposition.
After appropriate time points, cells were rinsed with nonsterile PBS and decalcified in
5mL of HCl for 24 hours. Afterwards, the HCl samples were collected and analyzed via Atomic
Absorption Spectroscopy (AAS) for quantification of calcium content. The cell layer was then
treated with 1mL of NaOH/0.1% SDS and then scraped and removed from the plates. Protein
concentration was then analyzed using a BCA Protein Kit (Pierce, Waltham, MA) Calcium
samples were normalized to the protein concentrations.
Scanning Electron Microscopy.
Cells were cultured and expanded to passage 7 and seeded onto plastic tissue culture
cover slips (60U2612, Sarstedt, Inc.) according to cell culture protocol. After a 7-day treatment
period, cells were gently rinsed with PBS and fixed with ½ Karnovsky’s fixative in 0.1 M
Sodium Cacodylate buffer for 1-2 hours. Following, cells underwent post fixation in 1%
Osmium Tetroxide for an hour and a were dehydrated in a graded ethanol series. Imaging was
then performed using Field Emission Scanning Electron Microscope at 10kV.
Atomic Force Microscopy
Cells were cultured and expanded to passage 7 and seeded onto plastic tissue culture
cover slips (60U2612, Sarstedt, Inc.) according to cell culture protocol for 7 days. Cells were
gently rinsed in PBS and imaged using Atomic Force Microscopy Bruker Dimension to record
average elastic (Young’s) modulus, stiffness, and height. This process involves using a noncoated nitride probe with varying tip radii. The average values of the mechanical properties were
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acquired from collecting random points across the surface of each sample. The modulus was
calculated via the Hertzian Model1 shown below, where F is the force from the force curve, E is
the Young’s Modulus, v is Poisson’s ratio, R is the tip radius, and δ is the indentation. Stiffness is
derived based on the linear graph.
𝐹=

4
𝐸
√𝑅𝛿 32
2
3 (1 − 𝑣 )

(1)

Staining
Cells were cultured and expanded to passage 7 and seeded according to cell culture
protocol in 4-well chamber slides. Cells were divided into treatment periods of 7 days and 14
days to stain for antibodies. After treatment period, cells were gently rinsed with PBS, fixed with
4% paraformaldehyde, permeabilized with 0.1% Triton X, and blocked with 5% PBSA. Cells
were then treated with primary antibodies and incubated in 4°C overnight. After incubation, the
primary antibody was removed and replaced with a secondary antibody and left for an hour at
room temperature in the dark lighting. After removing the secondary antibody, cells were stained
with Dapi and imaged via Light Microscopy. 7 Day cells were also stained with Xylenol Orange
to visualized calcium content.
Statistical Analysis.
Statistical significance was determined via one-way Analysis of Variance (ANOVA) and
T-Test at the α=0.05 level of significance.
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Results
Calcium content was quantified via Atomic Absorption (AA) and normalized to
protein concentration after 7 days of treatment of an inorganic phosphate source. As evident
from Figure 5, neither the low or high concentration of βGP or the 3mM Sodium Phosphate
Dibasic (SPD) significantly induced mineral deposition. However, the 3mM Sodium
Phosphate Dibasic Anhydrous (SPDA) was successful in calcifying VSMCs, as it displayed
the most mineralization compared to the other concentrations of inorganic phosphate. This
also confirmed our previous model of in-vitro calcification of VSMCs. After statistical
analysis, it was shown that there was significant difference among the values of calcium
content for each phosphate source. However, there was not a significant difference between
that of the 3mM SPDA and the 12mM SPDA/SPD. Since this was the case, 3mM SPDA was
used for all subsequent studies.

Figure 5

Calcium quantification of Human Aortic VSMCs treated with Sodium Dibasic
Phosphate Anhydrous (3mM, 6mM, 12mM), Sodium phosphate dibasic (3mM,
6mM, 12mM), and BGP (5mM & 10mM) for 7 days.

Cells were seeded in standard glass tissue culture plates. *Statistical significance was determined
by ANOVA & unpaired t-test (#) at significance level, p<0.05. (n=6)
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To determine the best cell culture environment, cells were seeded and calcified in
standard glass well plates and collagen coated well plates for 7 and 14 days. Figure 6 shows
that there was no significant difference between control nor calcified samples for each time
point. However, when comparing 7-day to 14-day samples, there was a significant increase
in calcium content. Since, there was no real difference between, standard glass well plates
were chosen as the appropriate cell culture environment.

Figure 6

Calcium quantification of Human Aortic VSMCs treated with 3mM Sodium Dibasic
Phosphate Anhydrous for 7 and 14 days.

Cells were seeded in standard glass tissue culture plates and collagen-coated well plates.
*Statistical significance was determined by ANOVA & unpaired t-test (#) at significance level,
p<0.05. (n=6)

Afterwards, VSMCs were treated with 3mM SPDA in standard glass well plates for 7
days to confirm that this was the most efficient in vitro model. As confirmed by t-test and
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shown in Figure 7, cells treated with 3mM SPDA had a significant increase in calcium
content as compared to healthy control cells.

Figure 7

Calcium quantification of Human Aortic VSMCs treated with 3mM Sodium Dibasic
Phosphate Anhydrous for 7 days.

Cells were seeded in standard glass tissue culture plates. Statistical significance was determined
unpaired t-test (#) at significance level, p<0.05. (n=6)
Cells were also stained with Xylenol Orange after being treated for 7 days to visualize
calcium content. Figure 8 is visualization of a healthy VSMC and as shown by Figure 8 (2),
there is virtually no expression of mineralization. However, Figure 9, which displays a calcified
cell, shows a definite increase in calcium content.
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Figure 8

Visualization of Calcium Content using Xylenol Orange Stain Ctrl.

(1) Standard light microscope image. (2) Visualization of calcium content using xylenol orange.
(3) Nuclei staining using Dapi. (4) Merged image with 3 channels.
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Figure 9

Visualization of Calcium Content using Xylenol Orange Stain Calc.

(1) Standard light microscope image. (2) Visualization of calcium content using xylenol orange.
(3) Nuclei staining using Dapi. (4) Merged image with 3 channels.
After confirming the inorganic phosphate source and growth environment and
visualizing calcium content, cells were calcified at 3- and 7-day time points to determine
when the onset of calcification occurs. As shown by Figure 10 and confirmed through
ANOVA, there was a significant difference of calcium content between the timepoints. Also,
there was a significant difference between the 3-day healthy cells and the 3-day calcified
cells as confirmed through t-test.
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Figure 10

Calcium quantification of Human Aortic VSMCs treated with 3mM Sodium Dibasic
Phosphate Anhydrous for 3 & 7 days.

Cells were seeded in standard glass tissue culture plates. Statistical significance was determined
by ANOVA and unpaired t-test (#) at significance level, p<0.05. (n=6)
Scanning electron microscopy (SEM) was another method used to visualize healthy vs
calcified cells after 7 days of treatment. Shown in Figure 11, control cells were frailer and more
damaged as compared to calcified cells after undergoing harsh SEM fixation protocols. There is
also visible calcium content within the calcified samples as shown in Figure 11 (5-6).
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Figure 11

SEM Visualization Control & Calcified Cells.

(1-2) Broad image of cell surface of both healthy and calcification samples. (3-4) Magnified
images of fewer cells on surface of healthy vs. calcified cells. (5-6) Single-cell images of health
vs calcified cells. Red circle indicated areas of suspected calcium deposition.

28

Calcified cells were also analyzed via Atomic Force Microscopy (AFM) for
mechanical properties. The Young’s (Elastic) Modulus and stiffness of the cells can be
determined by using the slope of the force curve after pinpointing different areas on the
surface of the cell. The modulus is directly correlated to the Hertzian model, and the stiffness
is recorded from a linear graph. Figure 12 displays the graphs for average modulus and
stiffness for healthy and calcified cells. The average modulus for calcified cells is much
larger than that of the healthy cells and as confirmed through t-test among stiffness values,
calcified cells were significantly harder than healthy cells.

Figure 12

AFM Average Modulus & Stiffness of Control vs. Calcified Cells.

Calcified cells exhibited a much larger modulus and stiffness compared to healthy cells as
confirmed through t-test (#).

29

Figure 13

AFM Visualization of Peak Height in Control vs. Calcified Cells

(1) Peak height for control cells is 519.6 nm. (2) Peak height for calcified cells is 766.4nm.

AFM was also used to visualize and determine heigh differences among healthy and
calcified cells. Shown in Figure 13, calcified cells had a higher height peak, 766.4nm,
compared to that of healthy cells, 519.6nm. The higher height peak was also associated with
more rigidity and stiffness.
Cells were stained at 7- and 14-day timepoints to visualize antibody expression.
Figure 14 shows staining for alpha-smooth muscle actin (SMA). The control sample, which
is a 14-day healthy cell displays a significantly larger concentration of SMA, as compared to
that of the 14day calcified samples, which is shows virtually no SMA expression. Also
shown is the gradual decrease of VSMC markers from 7 to 14 days of treatment. Figure 15
visualizes Axin1, which is an indicator of Wnt. Visibility of Axin1 also decreases as
calcification increases which is evident from the lack of expression in 14-day calcified
samples. Figure 16 shows RUNX2 expression in healthy and calcified cells. RUNX2 is
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shown to be increased in the nucleus, as calcification increases and gradually expressed in
more cells.

Figure 14

Alpha-Smooth Muscle Actin Staining: 7- vs. 14-day expression of SMA.

Significant decrease in expression of SMA as calcification time increases shown through the red
channel.
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Figure 15

AXIN1 Antibody Staining: 7- vs. 14-day expression of AXIN1.

Significant decrease in expression of AXIN1 as calcification time increases.
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Figure 16

RUNX2 Antibody Staining: 7- vs. 14-day expression of RUNX2.

Significant increase in expression of RUNX2 as calcification time increases.
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CHAPTER III
AIM II: INVESTIGATE THE DOSE DEPENDENCY OF SCLEROSTIN AS IT AFFECTS
VSMC CALCIFICATION
Introduction
A previous study performed by our lab had the primary focus manipulating the plasticity
of VSMCs to treat vascular calcification using SOST. Until this study, SOST had not yet been
evaluated as a treatment for calcification but revealed itself as a promising therapeutic agent. It
was shown that SOST inhibited phosphate-induced calcification, down-regulated the osteogenic
marker RUNX2, and even recovered a percentage of the vascular smooth muscle cell marker,
α−SΜΑ within the cell culture [40]. However, the study did not evaluate the effects of SOST at
different dosages and needs further examination to fully determine the effects of SOST as a
treatment.
Aim II Specific Objectives
The objectives of this study were to examine the effects of low and high dosages of
SOST treatment on calcified cells by quantifying and visualizing calcium content. We also want
to evaluate the effectiveness of the SOST treatments to halt and/or reverse the expression of
osteogenic markers in calcified cells and restore VSMC markers. As previously mentioned, we
believe that there will be strong correlation of increasing SOST treatment with the reduction in
calcium content and the recovery of VSMC markers.
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Experimental Section
Materials/Methods
Cell Culture.
Human Aortic VSMCs were cultured and expanded to passage 7. Cells were then seeded
in 6-well plates with 3mL of growth medium. Once grown to 80% confluency, plates were rinsed
with sterile PBS and supplemented with a “serum-starve” media for 12 hours. After the 12 hour
“starvation period”, calcification was then induced with Sodium Phosphate Dibasic Anhydrous
and calcified in time periods of 7 and 14 days. They were fed with their experimental media
every 2-3 days.
SOST Treatment.
Once plates reached day 7, cells were treated with SOST at 80ng/mL, our previous
treatment dosage, and 160ng/mL, doubling the original dosage. Cells treated with SOST
supplement continued to receive calcification media. After the end of each appropriate timeperiod, cells were rinsed with non-sterile PBS and decalcified in 5mL of HCl for 24 hours. HCl
samples were collected and analyzed via Atomic Absorption Spectroscopy (AAS) for
quantification of calcium content and normalized to protein concentration via BCA kit.
Staining.
Cells were cultured and expanded to passage 7 and seeded according to cell culture
protocol in 4-well chamber slides. Cells were divided into treatments of low SOST concentration
(80ng/mL) and high SOST concentration (160ng/mL). Slides were given their experimental
media throughout the entire duration of the study and were supplemented with SOST treatment
at day 7. At the study’s end, cells were gently rinsed with PBS, fixed with 4% paraformaldehyde,
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permeabilized with 0.1% Triton X, and blocked with 5% PBSA. Cells were then treated with
primary antibodies and incubated in 4°C overnight. After incubation, the primary antibody was
removed and replaced with a secondary antibody and left for an hour at room temperature in dark
lighting. After removing the secondary antibody, cells were stained with Dapi and imaged via
Light Microscopy. Plates were also stained with Xylenol Orange to visualize calcium content.
Results
Calcium content was quantified via Atomic Absorption (AA) and normalized to
protein concentration after 7 and 14 days of treatment of an inorganic phosphate source and
SOST supplementation. As evident from Figure 17 and confirmed via ANOVA, there was a
significant decrease in calcium content after being treated with both low and high
concentrations of SOST. There was also a significant difference and large decrease in
calcium content among low and high SOST treated samples. Cells treated with the high
concentration of SOST also showed lower calcium content than that of the 7-day calcified
cells.
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Figure 17

Calcium Quantification of Human Aortic VSMCs treated with 3mM Sodium
Dibasic Anhydrous and SOST for 7 & 14 days.

Cells were seeded in standard glass tissue culture plates and collagen-coated well plates.
Statistical significance was determined by ANOVA & post-hoc pairwise test at significance
level, p<0.05. Symbols indicate values that are statistically varying. (n=6)
Figure 18 shows calcium visualization in healthy, calcified, and SOST treated
samples. As seen by the second row or the red channels, there is no visible calcification in
control cells as compared to the remaining three calcification samples. However, there is a
gradual decrease in visual mineralization as the SOST treatment concentration increases.
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Figure 18

Visualization of Calcium Content using Xylenol Orange Stain after SOST
Treatment

The first row represents the standard light microscope image. The second row is visualization of
calcium content using xylenol orange on a Texas Red channel. The third row is nuclei staining
using Dapi. The fourth row is a merged image with red and blue channels.
Figure 19 and Figure 20 below aim to visualize markers associated with VSMC and the
Wnt-signaling pathway. It is clearly shown in Figure 19 that SMA was recovered after treatment
with SOST. It is also shown that the higher dosage of SOST recovered a greater amount of SMA
as opposed to the lower dosage of SOST treatment. Figure 20 shows AXIN1 expression in
healthy, calcified, and SOST treated samples. As seen by the second row or the red channels,
there is no visible expression in control in any of the samples.
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Figure 19

Alpha-Smooth Muscle Actin Staining: Expression of SMA after SOST Treatment.

Significant recovery of expression of SMA as SOST dosage increases. The first row represents
the standard light microscope image. The second row is visualization of calcium content using
xylenol orange. The third row is nuclei staining using Dapi. The fourth row is a merged image
with the red and blue channels.
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Figure 20

AXIN1 Antibody Staining: Expression of AXIN1 after SOST Treatment.

No recovery of expression of AXIN1 as SOST dosage increases. The first row represents the
standard light microscope image. The second row is visualization of calcium content using
xylenol orange. The third row is nuclei staining using Dapi. The fourth row is a merged image
with the red and blue channels.
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CHAPTER IV
DISCUSSION
Our original goals were to first characterize and confirm Wnt-signaling within invitro vascular calcification of VSMCs and investigate the dose dependency of SOST as a
treatment for vascular calcification. In our first experiment, we wanted to determine the best
inorganic phosphate source to induce calcification in VSMCs. Our previous research
confirmed that 3mM Sodium Phosphate Dibasic Anhydrous (SPDA) successfully induce
significant calcification, however, within a different VSMC lineage. Therefore, we wanted to
confirm our model still works for our current cell lineage. We saw an increase in calcium
content within cells that were treated with 3mM SPDA, 6mM SPDA and SPD, and 12mM
SPDA and SPD. However, the 3mM inorganic phosphate yielded the most calcium content
among the inorganic phosphate sources. This confirms our initial hypothesis and further
proves our previous research that 3mM SPDA successfully induces calcification and
significantly increases calcium content.
We also wanted to determine the best cell culture environment that would promote
growth and calcification. As previously mentioned, collagen has been shown to promote
calcification of VSMC, as some cells have been shown to produce collagen whilst in a
calcification state. To study this, we compared VSMCs seeded and calcified within standard
glass well plates to VSMCs seeded and calcified into collagen-coated well plates. Although
we saw an increase in calcium content in the cells grown in the collagen-coated plates, the
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difference was not significantly different from that of the cells grown in standard glass well
plates. We concluded that this is possibly due to the fact that the cells are already producing
collagen while they are calcifying, so adding them to a collagen environment does not
entirely create a different environment.
After confirming successful induction of calcification, we wanted to characterize invitro calcification. SEM imaging displayed the properties of the cells from their intactness
after the fixation protocol. Sample processing for SEM imaging involves a series of fixations
in Karnovsky’s fixative and Osmium Tetroxide and dehydration within a graded series of
ethanol. This prove to be a harsh environment for VSMCs, as shown by the damaged
membranes and visibility of the nucleus. However, calcified cells were seemingly not as
impaired compared to the control cells. To further confirm the mechanical properties of the
healthy versus calcified cells, we performed AFM. Imaging using AFM displayed a
significantly higher elastic modulus, stiffness, and peak height for cells treated with
inorganic phosphate. Therefore, we concluded that calcified cells are much harder, rigid, and
not as flexible as healthy cells. This further suggest that VSMCs in vascular calcification are
indeed undergoing a phenotypic modulation into osteoblast-like cells from their healthy
contractile phenotype.
When visualizing protein expression, there was a loss of SMA and AXIN and an
increase in RUNX2 expression in calcified cells. The loss of SMA and the gain of RUNX2
expression is consistent with previous literature and studies regarding the switch to
osteoblast-like cells and the involvement of Wnt-signaling. AXIN showed decreasing
expression in increasing calcification, although it is usually always present in some capacity.
As previously mentioned, the role of AXIN is to promote degradation of β-catenin to prevent
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Wnt-signaling. Therefore, the decrease of AXIN could be due to suppression because of the
accumulation of β-catenin. We can, however, conclude that Wnt-signaling is involved based
on the increasing expression of RUNX2 and the early expression of AXIN.
Lastly, we examined the effects of SOST treatment on calcification. When
investigating dosage dependency, we saw a decrease in calcium content of cells treated with
a low and high concentration of SOST. Moreover, VSMCs treated with high concentrations
of SOST showed a significantly lower calcium content than those treated with the low
concentrations SOST treatment. This confirms that supplementation of SOST has an
inhibitory effect on calcification, as well as confirms our hypothesis that it can be used as a
therapeutic agent. This was also confirmed through the visualization of calcium content and
antibodies after staining, where it is shown that calcium content decreases as the SOST
dosage increases. α-SMA was also successfully recovered after SOST treatment from both
low and high dosages. On the other hand, AXIN1 was not present in VSMC treated with
SOST. It is unclear why AXIN1 was not recovered after treatment, but it is possibly due to
the fact that as times proceeds, there is a gradual reduction in AXIN1 expression. This is also
in support of the concept that aging plays a role in the modulation of VSMCs to a synthetic
phenotype.
Concluding, our study was effective in characterizing and confirming the role of
Wnt-signaling. We were also able to identify VSMC and Wnt-signaling markers and track
their expression or lack-there-of during vascular calcification and determine mechanical
properties in correlation with healthy vs calcified cells. Most importantly, we were able to
confirm that SOST can be an effective method of combating calcification, further implicating
progression towards a treatment.
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CHAPTER V
FUTURE WORKS
The study proves that inorganic phosphate is effective with inducing calcification and
stimulating the phenotypic modulation of VSMCs. It was also further confirmed that our
previous in-vitro model of supplementing VSMCs with 3mM Sodium Dibasic Phosphate
Anhydrous is still successful with significant mineral deposition within a different cell line.
Moreover, SOST proves to be an effective therapy against calcification. These conclusions
are supported by quantification and visualization of calcium content in experimental cellculture plates at various time points. We also identified and characterized mechanical
properties of calcified/non-calcified VSMCs, as well as, stained for antibodies within
calcified cells and SOST-treated calcified cells. However, to ensure the true effectiveness of
the in-vitro model of calcification and SOST as a treatment, the study must be expanded to
include the following objectives:
1. Expand calcification studies to include examination of contractile and synthetic cells
to assess differences among cell phenotypes as it relates to calcium content.
2. Incorporate co-culture calcification studies with endothelial cells to create a better
model to represent the structure of an artery.
3. Perform ELISA to detect and quantify β-catenin in calcified cells after varying time
points, as well as, after SOST treatment.
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4. Perform Luciferase Reporter assays to quantify Wnt within cells that have been
supplemented with inorganic phosphate before and after they are treated with SOST
to assess the true effectiveness of SOST treatment on halting and/or reversing the
osteogenic phenotype.
5. Further expansion on the in-vitro model to include:
a. Treatment times extended beyond 14 days.
b. Antibody analyses at earlier timepoints to further pinpoint the initiation of
calcification.
c. Quantify protein expression in healthy vs. calcified cells.
d. Evaluate the mechanical properties of calcified cells at varying time points
and before and after SOST treatment.
In order for our model to be further evaluated in vivo, it is imperative to incorporate
the recommendations previously mentioned. It is also necessary to consider intimal vascular
calcification to determine the effectiveness of Sclerostin treatment. Although, our studies
prove to be promising and reliable in efforts to examine calcification and SOST.
SOST has evident potential in acting as treatment against calcification, however, its
mechanism by which it occurs also needs to be better understood. This should involve
determining the way by which its inhibition occurs and considering other key players that
may be involved. If these suggestions are to be applied, this would implicate a promising
progression towards a localized treatment for vascular calcification.
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